Stockreport

Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Hormone Receptor-Positive (HR+) Metastatic Breast Cancer (mBC) at 2018 American Society of Clinical Oncology (ASCO) Ann...

IMMUNOMEDICS  (IMMU) 
Last immunomedics earnings: 2/27 04:00 pm Check Earnings Report
PDF MORRIS PLAINS, N.J., April 25, 2018 (GLOBE NEWSWIRE) -- Immunomedics, Inc., (NASDAQ:IMMU) (“Immunomedics” or the “Company”), a leader in the field of antibody-drug con [Read more]